Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
P/E Ratio
--
P/B Ratio
0.25
Industry P/E
--
Debt to Equity
0.1
ROE
-0.58 %
ROCE
-53.22 %
Div. Yield
0 %
Book Value
1.54
EPS
-1.21
CFO
$-137.90 Mln
EBITDA
$-164.34 Mln
Net Profit
$-173.04 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sensei Biotherapeutics (SNSE)
| -22.46 | -25.24 | -22.73 | -62.75 | -39.07 | -- | -- |
|
BSE Sensex*
| 2.71 | 3.82 | 4.70 | 7.63 | 12.10 | 19.69 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Sensei Biotherapeutics (SNSE)
| -28.98 | -53.56 | -74.31 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly... selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Address: 1405 Research Boulevard, Rockville, MD, United States, 20850 Read more
President, CEO & Director
Mr. John K. Celebi M.B.A.
President, CEO & Director
Mr. John K. Celebi M.B.A.
Headquarters
Rockville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sensei Biotherapeutics Inc (SNSE) stood at $ 45 Mln as on 31-Dec-24
The share price of Sensei Biotherapeutics Inc (SNSE) is $0.38 (NASDAQ) as of 29-Apr-2025 16:09 EDT. Sensei Biotherapeutics Inc (SNSE) has given a return of -39.07% in the last 3 years.
Sensei Biotherapeutics Inc (SNSE) has a market capitalisation of $ 10 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sensei Biotherapeutics Inc (SNSE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sensei Biotherapeutics Inc (SNSE) and enter the required number of quantities and click on buy to purchase the shares of Sensei Biotherapeutics Inc (SNSE).
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Address: 1405 Research Boulevard, Rockville, MD, United States, 20850
The CEO & director of Mr. John K. Celebi M.B.A.. is Sensei Biotherapeutics Inc (SNSE), and CFO & Sr. VP is Mr. John K. Celebi M.B.A..
There is no promoter pledging in Sensei Biotherapeutics Inc (SNSE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Sensei Biotherapeutics Inc. (SNSE) | Ratios |
|---|---|
|
Return on equity(%)
|
-58.4
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sensei Biotherapeutics Inc (SNSE) was $0 Mln.
$-0.01
(
